Phase 3 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of Patients With WHIM Syndrome: Preliminary Results From Ongoing Open-Label Extension Period of Continuous Mavorixafor Treatment

被引：0

作者：

Tarrant, Teresa ^{[1
]}

Badolato, Raffaele ^{[2
,3
]}

Donadieu, Jean ^{[4
]}

Dubuc, Susan ^{[5
]}

Hu, Yanping ^{[6
]}

Jiang, Honghua ^{[7
]}

Li, Sunny ^{[8
]}

Steiner, Deborah ^{[9
]}

Yan, Tina ^{[8
]}

Arbet-Engels, Christophe ^{[10
]}

机构：

[1] Duke Univ, Dept Med, Div Rheumatol & Immunol, Med Rheumatol & Immunol, Durham, NC USA

[2] Univ Brescia, Dept Clin & Expt Sci, ASST Spedali Civili, Pediat,Chair Pediat, Brescia, Italy

[3] ASST Spedali Civili, Brescia, Italy

[4] CHU Paris Est, Hop Enfants Armand Trousseau, Paris, France

[5] X4 Pharmaceuticals, Pharmacovigilance & Risk Management, Boston, MA USA

[6] X4 Pharmaceuticals, Clin Res, Boston, MA USA

[7] X4 Pharmaceuticals, Biostatist, Boston, MA USA

[8] X4 Pharmaceuticals, Stat Programming, Boston, MA USA

[9] X4 Pharmaceuticals, Clin Dev, Boston, MA USA

[10] X4 Pharmaceuticals, Boston, MA USA

来源：

CLINICAL IMMUNOLOGY | 2024年 / 262卷

关键词：

WHIM syndrome; Combined immunodeficiency; CXCR4; antagonist; Mavorixafor; Phase 3 clinical trial; Neutropenia; Lymphopenia; Neutrophil; Rare disease; Primary immunodeficiency;

D O I：

10.1016/j.clim.2024.109949

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页数：3